NuvOx Pharma
1635 E 18th Street
Tucson
Arizona
85719
United States
Tel: 520-624-6688
Fax: 520-624-6699
Website: http://www.nuvoxpharma.com
Email: inquiry@nuvoxpharma.com
About NuvOx Pharma
NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. Due to inherent structure of DDFP, a very stable and relative lack of inter-molecular attractive forces, this perfluorocarbon is known to carry large payloads of oxygen in the bloodstream. The main advantage to using DDFP is that it is a liquid at room temperature, but expands to the gas state in the body. Therefore, upon intravenous injection the transition of DDFP from a liquid to a gas in the bloodstream allows for ~600 times increased oxygen transport compared to Hemoglobin.YEAR FOUNDED:
2008
LEADERSHIP:
Founder and CEO: Evan C. Unger
CFO: Betty R Weaver
COO: Rajan Ramaswami
JOBS:
Please click here for NuvOx job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
9 articles about NuvOx Pharma
-
NuvOx Completes Construction of Expanded Manufacturing Facility.
4/30/2021
NuvOx Pharma has completed construction and initiated operation of its GMP production facility for manufacturing its injectable pharmaceutical products at its Tucson, Arizona facility.
-
Health Canada Allows COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma's Oxygen Therapeutic in Phase IIa Clinical Trial
6/30/2020
NuvOx Pharma, a Tucson-based biotechnology company developing NanO2™ emulsion for oxygen delivery, has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).
-
NuvOx Pharma’s NVX-208 Shows Positive Results in Phase Ib/II Stroke Trial
2/8/2019
Positive results of NuvOx Pharma’s NVX-208 in the treatment of stroke have been published at the International Stroke Conference.
-
FDA Allows a Phase II Clinical Trial in Stroke for NuvOx Pharma’s DDFPe
1/31/2018
NuvOx Pharma announces that the FDA has allowed a Phase II clinical trial in 60 stroke patients to proceed to test NuvOx’s investigational drug product, dodecafluoropentane emulsion (DDFPe).
-
NCI Awards Grant To NuvOx Pharma For Phase II Clinical Trial In Brain Cancer
9/29/2017
-
NuvOx Pharma: Breathing New Life Into An Old Contrasting Agent
6/5/2017
-
FDA Allows NuvOx Pharma To Run A Phase II Clinical Trial In Brain Cancer
4/13/2017
-
NuvOx Pharma And University of Arkansas Initiate Phase Ib/II Clinical Trial In Stroke
3/8/2017
-
NuvOx Pharma And The University of Arkansas Initiate Phase Ib/II Clinical Trial In Stroke
3/6/2017